Ucci-Hn-15-01- Phase II Investigation Of Adjuvant Combined Cisplatin And Radiation With Pembrolizumab In Resected Hnscc
Posted Date: May 15, 2019
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The purpose of this research study is to determine the frequency and severity of side effects of Pembrolizumab when administered in combination with radiation alone or Cisplatin and radiation therapy (CRT) in patients undergoing adjuvant treatment for resected HNSCC.
Criteria:
To Be Eligible: Age 18 Or Older, Must Be Diagnosed With Resectable Hnscc. Nonpregnant/Breastfeeding, No Other Current Illness Or Malignancy
Keywords:
Cancer, Head And Neck, Hnscc, Resected, Ucci-Hn-15-01
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com